MX2023002970A - Esteres de acido ascorbico antitumorales. - Google Patents
Esteres de acido ascorbico antitumorales.Info
- Publication number
- MX2023002970A MX2023002970A MX2023002970A MX2023002970A MX2023002970A MX 2023002970 A MX2023002970 A MX 2023002970A MX 2023002970 A MX2023002970 A MX 2023002970A MX 2023002970 A MX2023002970 A MX 2023002970A MX 2023002970 A MX2023002970 A MX 2023002970A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- antitumoral
- acid esters
- ascorbic acid
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382804.1A EP3967684A1 (en) | 2020-09-14 | 2020-09-14 | Antitumoral ascorbic acid esters |
| PCT/EP2021/075104 WO2022053679A1 (en) | 2020-09-14 | 2021-09-13 | Antitumoral ascorbic acid esters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002970A true MX2023002970A (es) | 2023-05-15 |
Family
ID=72709280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002970A MX2023002970A (es) | 2020-09-14 | 2021-09-13 | Esteres de acido ascorbico antitumorales. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230278974A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3967684A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7805651B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102979182B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116724028B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021339010A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3191119A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3006988T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002970A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022053679A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120882410A (zh) * | 2023-03-09 | 2025-10-31 | 至善生医股份有限公司 | 包含13-顺式视黄酸和抗坏血酸的缀合化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2831395B2 (ja) * | 1989-09-12 | 1998-12-02 | ハリマ化成株式会社 | アスコルビン酸エステル |
| JP3781877B2 (ja) * | 1997-10-03 | 2006-05-31 | 株式会社ムック | アスコルビン酸誘導体またはその塩、および医薬 |
| CN101550119B (zh) * | 2009-05-11 | 2012-05-30 | 无锡宏瑞生物医药科技有限公司 | 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物 |
| CN102772402A (zh) | 2012-08-14 | 2012-11-14 | 中山大学 | 维生素c-布洛芬酯在制备脑靶向制剂中的应用及其制备方法 |
| JP2016104708A (ja) * | 2014-12-01 | 2016-06-09 | 参天製薬株式会社 | アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法 |
| JP6588764B2 (ja) * | 2015-01-26 | 2019-10-09 | 章博 田井 | 抗腫瘍剤 |
| CN106139151A (zh) * | 2016-04-29 | 2016-11-23 | 陈西敬 | 抗坏血酸棕榈酰酯与抗肿瘤药物协同作用的药物组合物 |
| EP3490543A4 (en) * | 2016-08-01 | 2020-04-01 | IC-Medtech Corp. | ASCORBIC ACID, CHINONE COMPOUND AND SODIUM GLUCOSE-COTRANSPORTER INHIBITOR FOR TREATING CANCER |
-
2020
- 2020-09-14 EP EP20382804.1A patent/EP3967684A1/en not_active Withdrawn
-
2021
- 2021-09-13 JP JP2023515364A patent/JP7805651B2/ja active Active
- 2021-09-13 MX MX2023002970A patent/MX2023002970A/es unknown
- 2021-09-13 EP EP21777302.7A patent/EP4211123B1/en active Active
- 2021-09-13 US US18/043,620 patent/US20230278974A1/en active Pending
- 2021-09-13 KR KR1020237012737A patent/KR102979182B1/ko active Active
- 2021-09-13 CA CA3191119A patent/CA3191119A1/en active Pending
- 2021-09-13 CN CN202180062720.9A patent/CN116724028B/zh active Active
- 2021-09-13 AU AU2021339010A patent/AU2021339010A1/en active Pending
- 2021-09-13 WO PCT/EP2021/075104 patent/WO2022053679A1/en not_active Ceased
- 2021-09-13 ES ES21777302T patent/ES3006988T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023541840A (ja) | 2023-10-04 |
| CN116724028B (zh) | 2025-07-08 |
| CN116724028A (zh) | 2023-09-08 |
| EP3967684A1 (en) | 2022-03-16 |
| JP7805651B2 (ja) | 2026-01-26 |
| EP4211123A1 (en) | 2023-07-19 |
| EP4211123B1 (en) | 2024-11-06 |
| CA3191119A1 (en) | 2022-03-17 |
| ES3006988T3 (en) | 2025-03-19 |
| WO2022053679A1 (en) | 2022-03-17 |
| EP4211123C0 (en) | 2024-11-06 |
| KR102979182B1 (ko) | 2026-06-19 |
| AU2021339010A1 (en) | 2023-03-23 |
| KR20230088718A (ko) | 2023-06-20 |
| US20230278974A1 (en) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000642A (es) | Compuestos macrociclicos para el tratamiento de cancer | |
| ZA202409114B (en) | MODULATORS OF THR-ß AND METHODS OF USE THEREOF | |
| RU2395500C2 (ru) | 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| PH12021552851A1 (en) | Nitrile-containing antiviral compounds | |
| CR20250329A (es) | Compuestos tricíclicos para el tratamiento del cáncer | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2023001379A (es) | Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a. | |
| CR20210602A (es) | Compuestos de pirrolidina | |
| MX2023003627A (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer. | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| IL205420A (en) | Immunogoldular and Derivative Compounds, Pharmaceutical Compounds in the Treatment of Inflammatory Stomach and Gastrointestinal Disorders | |
| MX2024003738A (es) | Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico. | |
| MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
| MX2025010357A (es) | Degradador de irak4, y uso del mismo | |
| GEAP202516765A (en) | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof | |
| MX2025014915A (es) | Lipidos que contienen amida | |
| MX2024009403A (es) | Tetrahidropiridopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| MX2025000635A (es) | Compuestos cíclicos y métodos de utilización de estos | |
| GEAP202516820A (en) | Prmt5-mta inhibitor | |
| MX2025013556A (es) | Benzimidazol y analogos relacionados para inhibir yap/taz-tead | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. |